Nature Reviews Clinical Oncology 14, 653–654 (2017)
In the illustration that accompanies this article, the structures of regorafenib and sorafenib were incorrectly drawn. In both structures, a double bond was omitted from the central phenyl ring so that it appeared as a 1,3-cyclohexadiene. The figure has been corrected in both the HTML and PDF versions of this News & Views.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2017.100
Rights and permissions
About this article
Cite this article
Gyawali, B., Prasad, V. Erratum: Me too-drugs with limited benefits — the tale of regorafenib for HCC. Nat Rev Clin Oncol 15, 62 (2018). https://doi.org/10.1038/nrclinonc.2017.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.190
